Biophan tightens grip on MRI (magnetic resonance imaging) safety sector:
This article was originally published in Clinica
Executive Summary
In what it claims gives it "market dominance in MRI safety", Biophan Technologies has been issued with a key US patent. The patent, explains the firm, is instrumental in securing the rights to its "anti-antenna" technology for making a broad range of medical apparatus - including pacemakers, surgical tools, and cardiovascular stents - safe for use with MRI systems. "Safety and image compatibility have long been major concerns when considering use of MRI ... with implanted devices," said Michael Weiner, the West Henrietta, New York firm's CEO. "We anticipate that this patent will protect the company's technology against the efforts of any other companies to make devices, such as pacemakers and neurostimulators, definitively safe for use with MRI machines."
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.